BioRender 图标

Neuroblastoma (SH-SY5Y, apoptosis)

Neuroblastoma (SH-SY5Y, apoptosis) - Editable icon of A differentiated SH-SY5Y neuroblastoma with a budding axon and a pyramidal body
[{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68c4/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68c4/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68c3/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68c3/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68c2/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68c2/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68c1/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68c1/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68c0/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68c0/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68bf/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68bf/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68be/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68be/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68bd/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68bd/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68bc/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68bc/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68bb/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68bb/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68ba/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68ba/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b9/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b9/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b8/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b8/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b7/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b7/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b6/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b6/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b5/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b5/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b4/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b4/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b3/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b3/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b2/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b2/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b1/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b1/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68b0/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68b0/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68af/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68af/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68ae/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68ae/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68ad/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68ad/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68ac/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68ac/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68ab/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68ab/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68aa/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68aa/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a9/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a9/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a8/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a8/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a7/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a7/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a6/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a6/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a5/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a5/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a4/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a4/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a3/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a3/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a2/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a2/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a1/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a1/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a68a0/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a68a0/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a689f/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a689f/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a689e/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a689e/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a689d/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a689d/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a689c/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a689c/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a689b/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a689b/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a689a/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a689a/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a6899/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a6899/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a6898/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a6898/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a6897/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a6897/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a6896/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a6896/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a6895/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a6895/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a6894/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a6894/630634847c75bb00281a6892.png"},{"image":"https://icons.cdn.biorender.com/w75xh75/630634f17c75bb00281a6893/630634847c75bb00281a6892.png","waterMarkImage":"https://icons.cdn.biorender.com/w550xh620/630634f17c75bb00281a6893/630634847c75bb00281a6892.png"}]
使用此图标 – 免费
注册无需信用卡。

此图标可在 BioRender 中完全编辑

  • 添加文本、形状及其他图标
  • 搜索 50,000 多种科学准确的图标
  • 重新着色并重新排列每一个图标、线条和标签
  • 导出或分享以满足任何使用需求
Scientist Avatars

加入 400 多万名科学家 的行列,制作可直接用于发表的图表

从图标到成品图表,只需几分钟

  • 搜索 来自 50,000 多个科学准确、经同行评审的图标
  • 自定义 添加标签、形状和更多图标——一切皆可完全编辑
  • 导出 或与协作者分享您的图表
    ‍

图标不合适?探索更多内容。

搜索涵盖 30 多个生命科学领域的 50,000 多个图标。

search icon
arrow-right
neuroblastoma,apoptosis,blebbing,cell death,programmed cell death,nuclear fragmentation,necrosis,capsase,protease,degradation,atrophy,SH-sy5y,SK-N-SH,parkinson,neurogenesis,differentiated,differentiation,n type,stress,stressed,SH-sy5y
查看更多

尝试使用同义词,或注册以在应用中请求图标。

图像类型

Neuroblastoma (SH-SY5Y, apoptosis) icon JPEG

Neuroblastoma (SH-SY5Y, apoptosis) icon PNG

Neuroblastoma (SH-SY5Y, apoptosis) icon SVG

Neuroblastoma (SH-SY5Y, apoptosis) icon GIF

BioRender 图标常见问题解答

How are scientists using the Neuroblastoma (SH-SY5Y, apoptosis) icon in their work?

BioRender users often use the Neuroblastoma (SH-SY5Y, apoptosis) icon in posters, grant applications, educational materials, and graphical abstracts. It’s especially useful for projects involving Cell Types.

我可以在 BioRender 图表或科学插图中使用此图标吗?

Yes, the Neuroblastoma (SH-SY5Y, apoptosis) is fully integrated into BioRender’s drag-and-drop platform. You can easily add it to any scientific figure, workflow, or poster, whether you’re building from scratch or starting with a BioRender template.

Is the Neuroblastoma (SH-SY5Y, apoptosis) icon customizable in BioRender?

Most icons in BioRender, including the Neuroblastoma (SH-SY5Y, apoptosis) icon, are customizable. You can adjust icon size, colors, and positioning, and add custom labels to tailor the design to your specific research context.

Can I export figures that include the Neuroblastoma (SH-SY5Y, apoptosis) icon for publication or presentations?

Yes, figures containing the Neuroblastoma (SH-SY5Y, apoptosis) icon can be exported in multiple formats, including PNG, JPG, PDF, and SVG. High-resolution and vector exports are available on paid plans, making them ideal for journals, slide decks, and print materials.

How do I cite BioRender if I use this icon?

Unlock publication permissions with a paid plan, and include 'Created with BioRender.com' in your figure legend, or cite BioRender directly per your journal's guidelines.

Is the Neuroblastoma (SH-SY5Y, apoptosis) icon used in BioRender templates or poster layouts?

Many BioRender templates include icons like the Neuroblastoma (SH-SY5Y, apoptosis) icon — especially those focused on Cell Types. You can search BioRender’s template library or add this icon manually to any canvas.

什么是 BioRender?

BioRender is a web‑based software that helps you create scientific figures in minutes. Use this Neuroblastoma (SH-SY5Y, apoptosis) icon along with our library of more than 30,000 life science icons.

在 BioRender 中使用此图标

立即开始制作专业的科学图表
antibody elements3D Phospholipid illustration

正在寻找科学内容?

浏览超过 5 万个经同行评审、易于使用且免费的图标和模板。

立即寻找您的专属素材
x icon